Oral sodium hydrogen carbonate versus placebo to reduce assisted delivery in nulliparous women with prolonged labour

3 1 1

What is this study about?

The study focuses on women who are having their first baby and who develop Prolonged labour, a condition where labor lasts longer than expected and can increase the chance of needing help to deliver the baby. The trial tests whether an oral solution of Sodium hydrogen carbonate can reduce the need for an emergency caesarean section or an instrumental vaginal birth compared with a placebo, and the purpose of the study is to compare the benefits and harms of the bicarbonate treatment with the placebo.

Participants are randomly assigned to receive either the bicarbonate solution or the placebo during labor and are followed through delivery. Researchers will record whether delivery required the defined assisted methods and will also note if the newborn needs to stay in a neonatal intensive care unit within the first day, as well as the mother’s reported birth experience using the Childbirth Experience Questionnaire. The trial continues only for the duration of labor and the immediate postpartum period, after which the collected data are analyzed.

1 enrollment and baseline information

after you agree to join the trial, basic health information and details about your pregnancy are recorded.

this information is used to confirm that you meet the study criteria for nulliparous women with prolonged labour.

2 random assignment to study medication

you will be randomly assigned to receive either the test medication samarin or a placebo.

the assignment is done by the study team and you will not know which one you receive.

3 receiving the oral medication

the medication is provided as an oral solution.

if you are assigned to the test group, the solution contains 16 g of sodium hydrogen carbonate (also known as bicarbonate).

if you are assigned to the placebo group, the solution contains only inactive ingredients such as glucose, sodium chloride, silica, and a lemon‑peach flavoring.

4 taking the medication during labour

when prolonged labour is diagnosed, you will be instructed to take the assigned oral solution.

the dose is a single administration of the 16 g solution, taken by mouth as directed by the clinical staff.

5 monitoring during delivery

your labour progress and any need for assisted delivery will be monitored.

assisted delivery includes an emergency caesarean section or an instrumental vaginal birth.

6 post‑delivery assessment

after birth, the health of the newborn is checked, including whether the child is admitted to a neonatal intensive care unit within the first 24 hours.

you will be asked to complete a questionnaire about your birth experience.

Who Can Join the Study?

  • Age 18 years or older
  • Can speak Danish or English
  • Pregnant with a single baby (not twins or multiples)
  • Baby positioned head‑first (cephalic presentation)
  • Pregnancy between 35 weeks and 41 weeks + 6 days (gestational age) when labour begins
  • Normal baby heart rate (fetal heart rate) recorded within the 20 minutes before joining the study
  • Labour started on its own (spontaneous onset) or started without medication using a balloon catheter or by breaking the water (non‑medical induced labour)
  • In the active first stage of labour: cervix opened at least 4 cm but less than 10 cm and having regular painful contractions (cervical dilatation and regular painful contractions)
  • Diagnosed with prolonged labour according to Danish guidelines

Who Cannot Join the Study?

  • Having a serious kidney (renal) or heart problem, which the doctors will review for each person.
  • Having a serious pregnancy‑related problem (obstetric complication) that the doctors consider a risk.
  • Being suspected of an infection, such as having a fever of 38.5 °C (101.3 °F) or higher if you have an epidural, or 38 °C (100.4 °F) or higher without an epidural, or if you have started broad‑spectrum antibiotics (medicines that treat many kinds of bacteria).
  • Receiving oxytocin to speed up or strengthen labor (called oxytocin augmentation) at the time you would be entered into the study.
  • Having a known allergy or intolerance to sodium bicarbonate (the chemical also known as baking soda).
  • Having taken sodium bicarbonate during active labor before being entered into the study.
  • Currently taking any of the following medicines: gabapentin (used for nerve pain), tetracycline (an antibiotic), or ketoconazole (an antifungal medication).

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Rigshospitalet Copenhagen Denmark
Ampxuz Urwnqpgjss Hfccdjhw Aarhus Denmark
Hhykzafd Hihdoxio Hvidovre Denmark

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Not yet recruiting
01.06.2026

Trial locations

Investigated Drugs:

Samarin is an oral solution that contains sodium hydrogen carbonate, a type of antacid. In this study it is given to women who are in the early stages of a long labor to see if it can lower the chance that they will need an assisted delivery, such as an emergency C‑section or the use of forceps or a vacuum. The medicine is taken by mouth and works by neutralizing acid in the stomach, which researchers think might influence how the uterus contracts during labor.

Prolonged labor – Prolonged labor is a condition in which the birth process lasts longer than the typical duration for a first‑time mother, often extending beyond 20 hours of active labor. It starts with regular uterine contractions that fail to open the cervix efficiently. Over time the cervical dilation progresses very slowly despite the continued effort of the uterus. The baby may remain high in the birth canal and does not move down as expected. As the labor continues, uterine strength can diminish, leading to weaker contractions. The prolonged nature of the process may eventually require assistance to complete the birth.

Trial ID:
2026-525682-45-00
NCT ID:
NCT07321379
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1
    Investigated Drugs:
    Belgium France Germany Hungary Italy Spain +1
  • Study on Datopotamab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic Endometrial, Gastric, Prostate, Ovarian, Colorectal, Urothelial, and Biliary Tract Cancers

    Recruiting

    2 1 1 1
    France Italy Poland Spain